Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 16/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340201 | 0.85 | CXCR2 (0.55) | CXCR2 | |
| SCHEMBL3337248 | 0.77 | CXCR2 (0.53) | CXCR2 | |
| SCHEMBL3344954 | 0.75 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL3343691 | 0.74 | CXCR2 (0.57) | CXCR2 | |
| SCHEMBL2638147 | 0.74 | CXCR2 (0.52) | CXCR2 | |
| SCHEMBL3367422 | 0.74 | CXCR2 (0.55) | CXCR2 | |
| SCHEMBL3344104 | 0.74 | CXCR2 (0.46) | CXCR2 | |
| SCHEMBL13304011 | 0.74 | CXCR2 (0.45) | CXCR2 | |
| SCHEMBL3339893 | 0.73 | CXCR2 (0.49) | CXCR2 | |
| SCHEMBL13304013 | 0.73 | CXCR2 (0.43) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| EP-2094697-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.